NICE approves innovative treatment for moderate to severe heart failureBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2402 (Published 27 April 2016) Cite this as: BMJ 2016;353:i2402
- Jacqui Wise
Doctors have a new treatment option for patients whose heart failure is not controlled by angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, after the National Institute for Health and Care Excellence (NICE) approved sacubitril valsartan (Entresto).1
Sacubitril valsartan is a novel treatment that includes both an angiotensin receptor neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan). Sacubitril works by restricting the action of neprilysin, a substance that prevents the dilation of blood vessels.
The guidance from NICE said that sacubitril valsartan is recommended for people with moderate …
Log in using your username and password
Log in through your institution
Sign up for a free trial